Key result
IV iron alleviates symptoms, improves quality of life, and reduces hospitalizations in HFrEF.
Why the study?
Iron deficiency is a common comorbidity in about 50% of patients with stable heart failure and is associated with worse clinical outcomes regardless of anaemia.
Does intravenous iron administration improve symptoms and outcomes in patients with heart failure and iron deficiency?
Does intravenous iron administration improve symptoms and outcomes in patients with heart failure and iron deficiency?
Intravenous iron is a promising therapy for correcting iron deficiency in heart failure with reduced ejection fraction, leading to improved symptoms and reduced hospitalizations.
Answers are grounded in this paper and cite their sources.
IV iron may ease symptoms and hospitalizations in HF with ID; leaves open optimal formulation, dosing, and hard-outcome confirmation.
Iron is an essential micronutrient for several physiological processes in the body beyond erythropoiesis. Iron deficiency (ID) is a common comorbidity observed in about 50% of patients with stable heart failure (HF) irrespective of the left ventricular function. The presence of ID is often as a multi-factorial condition, and it is associated with exercise intolerance, reduced quality of life, increased hospitalization rate, and mortality risk regardless of anaemia. The intravenous administration of iron to correct ID has emerged as a promising treatment in HF with reduced ejection fraction as it has been shown to alleviate symptoms, improve quality of life and exercise capacity, and reduce hospitalizations.
No takes yet. Share an insight, caveat, or question.
Caminiti et al. (2023) conducted a review in Heart failure with iron deficiency. Intravenous iron was evaluated. Intravenous administration of iron to correct iron deficiency in heart failure with reduced ejection fraction alleviates symptoms, improves quality of life, and reduces hospitalizations.
Synapse has enriched 10 related papers. Consider them for comparative context: